2016 Fiscal Year Final Research Report
Retroviral Replicating Vector (RRV)- Mediated Prodrug-Activator Gene Therapy for Pancreatic Cancer
Project/Area Number |
26461936
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
General surgery
|
Research Institution | Hokkaido University |
Principal Investigator |
Hiraoka Kei 北海道大学, 医学研究科, 客員研究員 (10719587)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Keywords | レトロウイルス / プロドラッグ / 膵癌 / 遺伝子治療 / ウイルスベクター |
Outline of Final Research Achievements |
In the present study, we are developing a retroviral replicating vector (RRV)-mediated prodrug activator gene therapy as a new therapeutic approach for pancreatic ductal adenocarcinoma. With this system, the prodrug (antifungal drug) is converted to the anticancer drug within RRV infected cells. In pancreatic cancer preclinical models, high levels of transduction were achieved and systemic administration of 5-FC resulted in significant inhibition of tumor growth.
|
Free Research Field |
医歯薬学 外科系臨床医学 外科学一般
|